EXAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exact Sciences Corp (EXAS) is not a strong buy for a beginner, long-term investor at this time. While the company has shown strong revenue growth, its significant decline in net income and EPS, coupled with neutral technical indicators and bearish sentiment from hedge funds, make it a less compelling investment currently. The lack of strong positive catalysts or proprietary trading signals further supports a hold recommendation.
The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negatively expanding, and the RSI is neutral at 48.78. The stock is trading near its pivot level of 103.33, with minor resistance at 103.605 and support at 103.055. Overall, there is no clear bullish momentum.
Revenue increased significantly by 23.12% YoY in Q4 2025, and gross margin improved to 70.11%, up 16.52% YoY. These indicate operational efficiency and growth potential.
Net income dropped drastically by -90.06% YoY, and EPS fell by -90.36% YoY, signaling profitability challenges. Hedge funds have significantly increased their selling activity (614.09% increase), and Evercore ISI downgraded the stock to In Line from Outperform. There are no recent congress trades or strong news catalysts specific to the company.
In Q4 2025, revenue increased to $878.38M (up 23.12% YoY), but net income dropped to -$85.96M (down -90.06% YoY). EPS also declined to -0.45 (down -90.36% YoY). Gross margin improved to 70.11% (up 16.52% YoY), reflecting operational efficiency despite profitability challenges.
Evercore ISI downgraded the stock to In Line from Outperform with an unchanged price target of $105. This reflects a neutral to slightly bearish sentiment from analysts.
